Davis Polk advised the sole book-running manager in connection with Galapagos NV’s offering of 4,312,500 ordinary shares in the form of American depositary shares, which includes the full exercise of the underwriter’s option to purchase additional ADSs. The offering resulted in gross proceeds to Galapagos of approximately €363.9 million ($388.1 million). The ADSs are listed on the NASDAQ Global Select Market under the symbol “GLPG.”

Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. The company’s pipeline comprises Phase 3, 2, 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications.

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Marcel Fausten and associates Martin Oberst and Chris Van Buren. The intellectual property and technology team included partner Pritesh P. Shah and associate Bonnie Chen. The tax team included counsel Alon Gurfinkel and associate Veronica Orecharova. The environmental team included counsel Loyti Cheng. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and London offices. 

Copy link to share post